Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Invested Capital: 2009-2025

Historic Invested Capital for Gyre Therapeutics (GYRE) over the last 17 years, with Sep 2025 value amounting to $137.4 million.

  • Gyre Therapeutics' Invested Capital rose 39.54% to $137.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.4 million, marking a year-over-year increase of 39.54%. This contributed to the annual value of $98.4 million for FY2024, which is 721.70% up from last year.
  • As of Q3 2025, Gyre Therapeutics' Invested Capital stood at $137.4 million, which was up 6.16% from $129.4 million recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Invested Capital high stood at $137.4 million for Q3 2025, and its period low was -$28.3 million during Q2 2023.
  • Over the past 3 years, Gyre Therapeutics' median Invested Capital value was $93.3 million (recorded in 2024), while the average stood at $62.1 million.
  • Per our database at Business Quant, Gyre Therapeutics' Invested Capital crashed by 195.82% in 2023 and then soared by 2,699.94% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Invested Capital (Quarterly) stood at $41.1 million in 2021, then surged by 75.76% to $72.2 million in 2022, then tumbled by 121.92% to -$15.8 million in 2023, then soared by 721.70% to $98.4 million in 2024, then skyrocketed by 39.54% to $137.4 million in 2025.
  • Its last three reported values are $137.4 million in Q3 2025, $129.4 million for Q2 2025, and $104.3 million during Q1 2025.